Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Arrowhead Pharma
(NASDAQ:ARWR)
Intraday
$22.12
0.25
[1.14%]
After-Hours
$22.12
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$22.12
0.25
[1.14%]
At close: Apr 26
$22.12
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Q2 2024 Earnings in 11 days from now on Thu May 9th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Arrowhead Pharma Stock (NASDAQ:ARWR)
Arrowhead Pharma Stock (NASDAQ: ARWR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 24, 2024
Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
Benzinga Newsdesk
-
3 days ago
Monday, April 08, 2024
Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24
Benzinga Newsdesk
-
Apr 8, 2024, 2:54AM
Thursday, April 04, 2024
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
Avi Kapoor
-
Apr 4, 2024, 7:23AM
Monday, March 25, 2024
Arrowhead Pharmaceuticals Initiates Expanded Access Program For Plozasiran
Benzinga Newsdesk
-
Mar 25, 2024, 8:05AM
Monday, March 11, 2024
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
Avi Kapoor
-
Mar 11, 2024, 10:37AM
Friday, March 08, 2024
Arrowhead Pharmaceuticals shares are trading higher after the company announced that it initiated its Phase 1/2a study of ARO-DM1 for the treatment of type 1 myotonic dystrophy.
Benzinga Newsdesk
-
Mar 8, 2024, 10:36AM
Arrowhead Pharmaceuticals Says It Initiated Phase 1/2a Study Of ARO-DM1 For Treatment Of Type 1 Myotonic Dystrophy, Company Adds ARO-DM1 Is Designed To Reduce Expression Of Dystrophia Myotonica Protein Kinase (DMPK) Gene In Muscle
Benzinga Newsdesk
-
Mar 8, 2024, 7:34AM
Friday, March 01, 2024
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Mar 1, 2024, 11:18AM
Wednesday, February 28, 2024
Blog Chatter Suggests "People Following The Situation Have Heard Speculation Arrowhead Pharmaceuticals Recently Rebuffed An Indicative Approach Pitched At Around $45 A Share."; Shares Spiking Higher
Benzinga Newsdesk
-
Feb 28, 2024, 1:20PM
Watching Arrowhead Pharmaceuticals; Traders Circulating M&A Blog Chatter Sugging The Company Is Seeing Takeover Interest
Benzinga Newsdesk
-
Feb 28, 2024, 1:18PM
Thursday, February 08, 2024
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Benzinga Newsdesk
-
Feb 8, 2024, 3:27PM
Wednesday, February 07, 2024
Citigroup Maintains Neutral on Arrowhead Pharma, Raises Price Target to $34
Benzinga Newsdesk
-
Feb 7, 2024, 2:07PM
Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma
Benzinga Insights
-
Feb 7, 2024, 12:01PM
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price Target
Benzinga Newsdesk
-
Feb 7, 2024, 11:55AM
Arrowhead Pharma shares are trading lower after the company reported worse-than-expected Q1 financial results.
Benzinga Newsdesk
-
Feb 7, 2024, 8:26AM
Tuesday, February 06, 2024
Arrowhead Pharma shares are trading lower after the company reported worse-than-expected Q1 financial results.
Benzinga Newsdesk
-
Feb 6, 2024, 4:37PM
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Feb 6, 2024, 4:31PM
Recap: Arrowhead Pharma Q1 Earnings
Benzinga Insights
-
Feb 6, 2024, 4:10PM
Arrowhead Pharma Q1 EPS $(1.24) Misses $(0.82) Estimate, Sales $3.55M Miss $29.51M Estimate
Benzinga Newsdesk
-
Feb 6, 2024, 4:07PM
Earnings Scheduled For February 6, 2024
Benzinga Insights
-
Feb 6, 2024, 5:42AM
Tuesday, January 16, 2024
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price Target
Benzinga Newsdesk
-
Jan 16, 2024, 9:17AM
Thursday, January 04, 2024
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Jan 4, 2024, 10:12AM
Wednesday, January 03, 2024
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Jan 3, 2024, 12:58PM
Why Arrowhead Pharmaceuticals Shares Are Moving
Henry Khederian
-
Jan 3, 2024, 10:30AM
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Jan 3, 2024, 10:24AM
Arrowhead Pharmaceuticals Reports Pricing Of Offering Of 15.79M Shares At $28.50 Per Share; Gross Offering Proceeds Will Be Approximately $450M
Benzinga Newsdesk
-
Jan 3, 2024, 7:01AM
Tuesday, January 02, 2024
4 Analysts Assess Arrowhead Pharma: What You Need To Know
Benzinga Insights
-
Jan 2, 2024, 3:00PM
B of A Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $37
Benzinga Newsdesk
-
Jan 2, 2024, 11:07AM
Friday, December 29, 2023
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Surbhi Jain
-
Dec 29, 2023, 8:34AM
Thursday, December 21, 2023
Arrowhead Pharmaceuticals Files An Application In New Zealand For Clearance To Initiate A Phase 1/2A Trial Of ARO-CFB For Complement Mediated Renal Disease
Benzinga Newsdesk
-
Dec 21, 2023, 7:37AM
Monday, December 04, 2023
What 4 Analyst Ratings Have To Say About Arrowhead Pharma
Benzinga Insights
-
Dec 4, 2023, 4:00PM
B of A Securities Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $29
Benzinga Newsdesk
-
Dec 4, 2023, 7:42AM
Thursday, November 30, 2023
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Nov 30, 2023, 1:13PM
Arrowhead Pharmaceuticals shares are trading lower after the company reported FY23 results.
Benzinga Newsdesk
-
Nov 30, 2023, 10:37AM
Morgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Lowers Price Target to $37
Benzinga Newsdesk
-
Nov 30, 2023, 10:14AM
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $50 Price Target
Benzinga Newsdesk
-
Nov 30, 2023, 9:54AM
Wednesday, November 29, 2023
Recap: Arrowhead Pharma Q4 Earnings
Benzinga Insights
-
Nov 29, 2023, 4:45PM
Arrowhead Pharmaceuticals Reports FY23 EPS Of $(1.92) Vs (1.67) Last Year; Revenue $240.735M Vs $243.23M Last Year
Benzinga Newsdesk
-
Nov 29, 2023, 4:05PM
Earnings Scheduled For November 29, 2023
Benzinga Insights
-
Nov 29, 2023, 7:46AM
Tuesday, November 28, 2023
Earnings Outlook For Arrowhead Pharma
Benzinga Insights
-
Nov 28, 2023, 9:01AM
Arrowhead Pharmaceuticals Has Filed An Application For Clearance To Initiate A Phase 1/2A Trial Of ARO-DM1 In New Zealand For Type 1 Myotonic Dystrophy, The Most Common Adult-onset Muscular Dystrophy
Benzinga Newsdesk
-
Nov 28, 2023, 7:32AM
Monday, November 13, 2023
Arrowhead Presents New Phase 2 Data On Plozasiran And Zodasiran At AHA 2023
Benzinga Newsdesk
-
Nov 13, 2023, 9:31AM
Tuesday, October 31, 2023
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
Vandana Singh
-
Oct 31, 2023, 11:05AM
Thursday, September 21, 2023
Arrowhead Pharma Chief Executive Officer Trades $1.62M In Company Stock
Benzinga Insights
-
Sep 21, 2023, 11:04AM
Chief Executive Officer at Arrowhead Pharma Acquires Company Stock Options Worth 57,555 Shares
Benzinga Insights
-
Sep 21, 2023, 11:01AM
Tuesday, September 19, 2023
Analyst Expectations for Arrowhead Pharma's Future
Benzinga Insights
-
Sep 19, 2023, 11:00AM
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
Benzinga Insights
-
Sep 19, 2023, 11:00AM
Citigroup Initiates Coverage On Arrowhead Pharma with Neutral Rating, Announces Price Target of $33
Benzinga Newsdesk
-
Sep 19, 2023, 5:47AM
Friday, September 08, 2023
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
Lisa Levin
-
Sep 8, 2023, 9:24AM
Thursday, August 10, 2023
Watching Arrowhead Pharmaceuticals; Zacks Small-Cap Research Sets $80 Price Valuation; Says This Model Is Highly Dependent Upon The Continued Clinical Success Of Those Programs And Will Be Adjusted Accordingly Based Upon Future Clinical Outcomes
Happy Mohamed
-
Aug 10, 2023, 12:13PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch